Novo Nordisk Stock Plummets After Ozempic-Maker's Alzheimer's Drug Trial Fails

Core Viewpoint - Novo Nordisk's shares experienced a significant decline after the failure of its trials testing the impact of Ozempic on Alzheimer's disease progression, marking the lowest level since July 2021 [1][2]. Group 1: Stock Performance - Shares of Novo Nordisk fell by more than 12% initially, recovering slightly to Kr 273.35 ($42.25), which represents a decrease of approximately 10.3% [1]. - The company's stock has decreased by 57.2% since the beginning of 2025 and is over 72% lower than its peak in June 2024, when it reached Kr 1,000 ($154.5) [4]. Group 2: Trial Results - The trials involved 3,808 adults and aimed to assess the effect of semaglutide, the active ingredient in Ozempic, on Alzheimer's disease progression, but did not meet their primary goal [2]. - Cognitive assessments indicated that patients receiving semaglutide did not show significant slowing in disease progression compared to the placebo group [2]. - Despite showing "improvement of Alzheimer's disease-related biomarkers" in both trials, the drug failed to slow the neurodegenerative disease [3]. - The trials targeted patients aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer's disease, and the company will discontinue a planned one-year extension of the studies [3].